PT - JOURNAL ARTICLE AU - Zhu, Yuyu AU - Shao, Fenli AU - Yan, Wei AU - Chen, Zhen Bouman AU - Ke, Bowen AU - Jiang, Xian AU - Cheng, Haibo AU - Sun, Dongdong AU - Song, Chenglin AU - Kong, Lingdong AU - Guo, Wenjie AU - Lai, Yuping AU - Feng, Gen-Sheng AU - Xu, Qiang AU - Sun, Yang TI - Inhibition of SHP2 ameliorates psoriasis by decreasing TLR7 endosome localization AID - 10.1101/2020.09.28.20202861 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.28.20202861 4099 - http://medrxiv.org/content/early/2020/09/30/2020.09.28.20202861.short 4100 - http://medrxiv.org/content/early/2020/09/30/2020.09.28.20202861.full AB - Psoriasis is a complex chronic inflammatory skin disease with unclear molecular mechanisms. Here, we identify Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) as a novel accelerator of psoriasis development. Both genetic ablation of SHP2 in macrophages and pharmacological inhibition of SHP2 prevents the development of psoriasis-like skin inflammation in an imiquimod-induced murine model of psoriasis. Mechanistically, SHP2 promotes the trafficking of Toll-like receptor 7 (TLR7) from Golgi to endosome through its interaction with and dephosphorylation of TLR7 at Tyr1024, which promotes the ubiquitination of TLR7 and psoriasis-like skin inflammation. Importantly, SHP2 allosteric inhibitor SHP099 reduces the expression of pro-inflammatory cytokines in peripheral blood mononuclear cells from human patients with psoriasis. Collectively, our findings identify SHP2 as a novel regulator of psoriasis and suggest that SHP2 inhibition may be a promising therapeutic approach for psoriatic patients.Competing Interest StatementY.S. and Q.X. have a patent pending on use of SHP2 inhibitors in psoriasis (202010109716.0). The other authors declare no conflict of interest.Funding StatementThis work was supported by National Natural Science Foundation of China (Nos. 81872877, 81730100, 91853109, 81673436, 81803142), and Mountain-Climbing Talents Project of Nanjing University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Animal welfare and experimental procedures were approved by the Institutional Animal Care and Use Committee at Nanjing University. All human studies were approved by the Ethics Institutional Review Board of West China Hospital, Sichuan University.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RNA-seq data have been deposited to the Gene Expression Omnibus with accession no. GSE147535. All other data needed to evaluate the conclusions in this manuscript are present in the paper.